A review of CCR5 antibodies against HIV: current and future aspects
- PMID:30729884
- DOI: 10.4155/tde-2018-0072
A review of CCR5 antibodies against HIV: current and future aspects
Abstract
HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide. There has been tremendous research and development in the diagnosis, prevention and treatment of HIV. Small molecules have been shown to reduce the virus to nondetectable level in human plasma, however, there are reservoirs of latent virus that reemerge if antiretroviral therapy is stopped. There is no vaccine to prevent or cure HIV. A significant amount of research has been reported in the literature regarding antibodies for CCR5, a HIV entry host receptor. This report describes the role of CCR5 antibody in HIV prevention/treatment and how antibody-conjugated nanoparticles could be a future strategy with the potential to effectively eradicate the virus from the human system.
Keywords: CCR5; HIV; monoclonal antibody; nanoparticles; parenteral delivery system.
Similar articles
- Monoclonal CCR5 Antibody: A Promising Therapy for HIV.Zhao L, Lai Y.Zhao L, et al.Curr HIV Res. 2023;21(2):91-98. doi: 10.2174/1570162X21666230316110830.Curr HIV Res. 2023.PMID:36927434Review.
- Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.Madrid-Elena N, García-Bermejo ML, Serrano-Villar S, Díaz-de Santiago A, Sastre B, Gutiérrez C, Dronda F, Coronel Díaz M, Domínguez E, López-Huertas MR, Hernández-Novoa B, Moreno S.Madrid-Elena N, et al.J Virol. 2018 Apr 13;92(9):e01931-17. doi: 10.1128/JVI.01931-17. Print 2018 May 1.J Virol. 2018.PMID:29444937Free PMC article.
- CCR5 monoclonal antibodies for HIV-1 therapy.Olson WC, Jacobson JM.Olson WC, et al.Curr Opin HIV AIDS. 2009 Mar;4(2):104-11. doi: 10.1097/COH.0b013e3283224015.Curr Opin HIV AIDS. 2009.PMID:19339948Free PMC article.Review.
- Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR.Latinovic OS, et al.Curr HIV Res. 2016;14(1):24-36. doi: 10.2174/1570162x13666150909145150.Curr HIV Res. 2016.PMID:26354735
- Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.Jekle A, Chhabra M, Lochner A, Meier S, Chow E, Brandt M, Sankuratri S, Cammack N, Heilek G.Jekle A, et al.Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7.Antimicrob Agents Chemother. 2010.PMID:19995923Free PMC article.
Cited by
- Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis.Amerzhanova Y, Vangelista L.Amerzhanova Y, et al.Front Immunol. 2022 Jan 19;13:826418. doi: 10.3389/fimmu.2022.826418. eCollection 2022.Front Immunol. 2022.PMID:35126399Free PMC article.
- Molecular Role of HIV-1 Human Receptors (CCL5-CCR5 Axis) in neuroAIDS: A Systematic Review.Silva MJA, Marinho RL, Rodrigues YC, Brasil TP, Dos Santos PAS, Silva CS, Sardinha DM, Lima KVB, Lima LNGC.Silva MJA, et al.Microorganisms. 2024 Apr 12;12(4):782. doi: 10.3390/microorganisms12040782.Microorganisms. 2024.PMID:38674726Free PMC article.Review.
- The Role of CCL3 in the Pathogenesis of Rheumatoid Arthritis.Yang YL, Li XF, Song B, Wu S, Wu YY, Huang C, Li J.Yang YL, et al.Rheumatol Ther. 2023 Aug;10(4):793-808. doi: 10.1007/s40744-023-00554-0. Epub 2023 May 25.Rheumatol Ther. 2023.PMID:37227653Free PMC article.Review.
- CCR5 Promoter Polymorphism -2459G > A: Forgotten or Ignored?Mehlotra RK.Mehlotra RK.Cells. 2019 Jun 28;8(7):651. doi: 10.3390/cells8070651.Cells. 2019.PMID:31261839Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical